Drug development company Chelsea Therapeutics plans to file a new drug application in the third quarter for its lead drug candidate, an orphan drug for Parkinson’s disease patients. Charlotte, North Carolina-based Chelsea (NASDAQ:CHTP) reaffirmed the plans following correspondence with the U.S. Food and Drug Administration regarding data from a recent study on its drug candidate […]
Chelsea Therapeutics wants to raise $35 million through a stock offering that will finance work on drug candidates for hypotension and rheumatoid arthritis.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Chelsea Therapeutics' low blood pressure drug Northera fails to meet its primary target in phase III clinical trials and the Charlotte, North Carolina-based company now says it is expanding its study of the drug candidate for a different target.